Современная онкология | 卷:23 |
Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence | |
Elena A. Dmitrieva1  Eugene A. Nikitin1  Andrei A. Petrenko1  Maria I. Kislova2  | |
[1] Botkin City Clinical Hospital; | |
[2] Sechenov First Moscow State Medical University (Sechenov University); | |
关键词: acalabrutinib; ibrutinib; bruton tyrosine kinase inhibitors; target agents; chronic lymphocytic leukemia; atrial fibrillation; bleeding; | |
DOI : 10.26442/18151434.2021.2.200957 | |
来源: DOAJ |
【 摘 要 】
Chronic lymphocytic leukemia (CLL) treatment landscape has changed dramatically with the recently developed drugs targeting the B-cell receptor (BCR) signalling pathway. Acalabrutinib, a second generation Bruton tyrosine kinase inhibitor, was approved in 2020 in Russia for the treatment of patients with CLL. Acalabrutinib was developed as a more selective Bruton tyrosine kinase inhibitor then ibrutinib. This drug is aimed at reducing the adverse events that limit the use of ibrutinib, such as atrial fibrillation and bleeding. Phase I/II multicenter studies have demonstrated the efficacy and safety of acalabrutinib monotherapy in untreated CLL patients and in patients with relapsed/refractory CLL and ibrutinib intolerance. Phase III trials, ASCEND and ELEVATE-TN, compared acalabrutinib monotherapy and a combination of acalabrutinib and obinutuzumab versus standard therapies and demonstrated improved efficacy and tolerability of acalabrutinib. A phase III trial comparing acalabrutinib and ibrutinib monotherapy (ELEVATE-RR) is ongoing. The results of this study along with real-life clinical data could determine the place of acalabrutinib in CLL treatment.
【 授权许可】
Unknown